top of page

European Commission approves transfer of marketing authorisation for Alprolix to Sobi

The European Commission (EC) has approved the transfer of the marketing authorization for Alprolix (eftrenonacog alfa), a recombinant clotting factor therapy developed for the treatment of haemophilia B, from Biogen to Swedish Orphan Biovitrum (Sobi), making Sobi the marketing authorization holder (MAH) in the EU.

Click on this link for more information.


Today's News
Follow us
  • LinkedIn Social Icon
  • Vimeo Social Icon
Newsletter on Pharma Legislation
the newsletter of
bottom of page